Resiliency - What To Do When Your Supply Chain Breaks
Client Alert | 2 min read | 04.01.20
In times of correlated financial stress, no manufacturer needs a disruption in the flow of critical components through its supply chain. Apart from the supply chain disruption, the manufacturer’s liquidity may be constrained due to limited financial resources, reduced inventory or receivables for borrowing base calculations, fully drawn lines of credit and, in the worst case, one or more defaulting lenders. The manufacturer’s revenue may have fallen due to decreased demand for the goods in the marketplace and performing customers may bargain for extended payment terms. Adding the failure of a critical supplier increases the manufacturer’s misery and requires urgent brainstorming.
The standard manufacturer playbook for supplier default starts with a search for alternative vendors. If other vendors are not readily available, perhaps because the needed component is bespoke and integral to the final product, manufacturers offer financial support to a troubled supplier. Loans, convertible notes, or convertible preferred equity are common financial structures and instruments deployed to rehabilitate stressed suppliers.
Under the standard model, the financing is designed to provide a key supplier enough liquidity to continue operating, and often includes an equity kicker for the manufacturer’s benefit. However, if the manufacturer is financially constrained, or if the supplier is in extreme difficulty, then financial support will be insufficient to carry the supplier through the crisis. In these types of cases, manufacturer-provided financing will not ensure supply chain resiliency over the long haul.
Recently, one of our manufacturing clients had a novel solution - buying the specific plant, equipment and intellectual property used by the supplier to manufacture the critical component. Structurally, the transaction was a “carveout” transaction, in which the specific (mission-critical) plant, equipment, and related IP were all purchased, and the supplier’s manufacturing know-how was transferred to the manufacturer and made available to its employees. This allowed the manufacturer to take full and lasting control of a critical link in the supply chain.
In contrast, while a loan or other financing transaction might have solved supplier’s short-term liquidity issues, such a financing may have left the manufacturer vulnerable to a second round of supply chain disruption if the period of market stress persisted. Purchasing a bespoke and narrow range of plant, equipment and IP proved to be the sturdier solution.
We are in challenging times, and supply continuity is a continuing concern. Given the uncertainty as to the duration of the current financial crisis, it makes sense to fashion legal solutions that prioritize manufacturer-control and resilient (truncated) supply chain architecture. In some cases the novel approach will outperform solutions that will require constant further attention and support.
Contacts
Insights
Client Alert | 8 min read | 04.17.26
CMS Finalizes CY 2027 Medicare Advantage and Part D Rule: Key Implications for Plan Sponsors
On April 6, 2026, the Centers for Medicare & Medicaid Services (CMS) published its final rule governing the Medicare Advantage (Part C) and Prescription Drug Benefit (Part D) programs for Contract Year (CY) 2027. The final rule is effective June 1, 2026, with most provisions applicable to coverage beginning January 1, 2027, and marketing and communications changes taking effect October 1, 2026. Beyond payment, the rule pursues a broad deregulatory agenda aligned with Executive Order 14192, reversing marketing and enrollment safeguards introduced in 2023 and easing documentation and reporting obligations, while introducing new program integrity requirements.
Client Alert | 1 min read | 04.17.26
Client Alert | 3 min read | 04.17.26
Client Alert | 2 min read | 04.16.26

